anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain the titled polysaccharide useful as an antitumor agent simply in a large scale, by extracting bark of Melia azadirachata Linn. with hot water, purifying the extracted solution by dialysis membrane method, etc., bringing it into contact with specific dextran gel, collecting it from the contacted aqueous solution. CONSTITUTION:Bark of Melia azadirachata Linn is extracted with hot water, the extracted solution is purified by dialysis membrane method, alcohol precipitation method, or ultrafiltration. The prepared extracted solution is brought into contact with crosslinked dextran gel having 700-5,000 upper limit of fractionated molecular weight range and &lt;=100 lower limit, and polysaccharide N9GI (lyophilized polysaccharide N9GI is white powder or light yellowish brown powder; soluble in water, insoluble in an organic solvent such as methanol, etc.; positive in phenol sulfuric acid reaction, etc. and addition of iodine shows blue green) is obtained from he contacted aqueous solution. The dextran gel used as an adsorbent is preferably required to have improved mechanical strength, and high crosslinking.
FIELD: recording accessories. SUBSTANCE: the instrument has a reservoir of fiber having ducts and a pen of porous material with ducts providing for passage of ink through it. The composition of ink in the reservoir includes a colored pigmented dispersion and a dispersion of aluminum pigment with particles measuring not more than 12 microns. The pen is contiguous to the reservoir and can absorb the dispersion of aluminum pigment as a result of capillary action. Offered is also the method for making of temporary tattoos on the human skin including the stages of production of the recording instrument having a reservoir of tightly packed polyester oriented fiber with ducts providing for passage of ink through it, as well as of the composition of ink in the reservoir mentioned above. The temporary tattoos representing wipe-off non-transparent &#34;metal&#34; lines are produced by pressing of the recording instrument on the human skin. EFFECT: enhanced reliability of action. 18 cl, 2 dwg, 6 tbl
One embodiment of the present invention is a compound represented by Structural Formula (I) wherein Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both &gt;C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or -C(RR)-. Ris an aliphatic group, a substituted aliphatic group, a non- aromatic hetereocyclic group, or a substituted non-aromatic hetereocyclic group, R-Rare independently -H, an aliphatic group, a substituted aliphatic group, a non-aromatic hetereocyclic group, a substituted non-aromatic hetereocyclic group, an aryl group or a substituted aryl group, or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, and/or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R-Rare independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. Rand Rare each independently -H, an aliphatic or substituted aliphatic group, or Ris -H and Ris a substituted or unsubstituted aryl group, or, Rand R, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is =0 or =S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide polyvinyllactam cross-linked product fine particles which improves a problem that polyvinyllactam product particles having an average particle diameter of &gt;1μm are liable to adhere to each other due to their hygroscopicity and can hardly be crushed into the fine particles, because of having a large cohesive force, and to provide a method for producing the same.  &lt;P&gt;SOLUTION: The highly cohesive / adhesive polyvinyllactam cross-linked product can be crushed into a fine particle diameter with a crusher without reaggregating the particles. The polyvinyllactam cross-linked fine particles have an average particle diameter of ≤1μm. A polyvinyllactam cross-linked product fine particle dispersion is obtained by dispersing the polyvinyllactam cross-linked product fine particles in a dispersant. The method for producing the polyvinyllactam cross-linked product fine particles comprises mechanically crushing the polyvinyllactam cross-linked fine particles have an average particle diameter of &gt;1μm into an average particle diameter of ≤1μm.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The present invention relates to a Chinese medicine preparation for curing hyperplasia of mamary glands and a preparation method thereof. The Chinese medicine preparation of the present invention is prepared by the uniform blending of 0.05 to 4 parts of dragon&#39;s blood and 3 to 50 parts of pangolin scale according to a weight proportion. Besides, notoginseng, sappanwood, etc. can also be added; the pangolin scales are stir-fried with table vinegar or uniformly mixed with sand, and are stir-fried until yellow and sieved for use. The Chinese medicine preparation has the advantages of reasonable prescription and convenient preparation, and has the functions of relieving the depressed liver, rectifying qi, promoting blood circulation and dissipating masses. The Chinese medicine preparation has special therapeutic effect on hyperplasia of mamary glands, and has good therapeutic effect on early mammary cancer.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic for infrared protection having improved protection unevenness of infrared reflecting effects after coating without uneven application during coating of the cosmetic.  &lt;P&gt;SOLUTION: The cosmetic is obtained by including (1) hollow resin spherical powder which may be coated with a metal oxide and (2) boron nitride powder. The hollow resin spherical powder which may be coated with the metal oxide preferably consists essentially of polyacrylonitrile and may be coated with the metal oxide. Titanium dioxide is preferably used as the metal oxide for coating in the hollow resin spherical powder which may be coated with the metal oxide. The average particle diameter of the hollow resin spherical powder is preferably 10-30 μm and preferably for the protection from infrared rays.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an eye washer capable of eliminating the need of repeatedly using a cup to prevent contamination of germs and attain a high safety, and dispensing with an antisepic agent mixed so as to be low-irradiating to the eye.  &lt;P&gt;SOLUTION: In this eye washer, an eye washing lotion at least containing drug is put in a unit dose type eye washing cup, and a film-like lid part is provided. Preferably, the drug is at least one kind of a resolution and astringent, antihistamine, vitamins and amino acids, or it contains trometamol. The eye washing cup is formed of flexible raw material whose light transmittance is 10% or lower at a wavelength ranging from 200 nm to 380 nm. The lid part includes a laminate of a resin sheet layer and an aluminum sheet layer.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
A system and method for identifying individuals that compatibly contribute to high-performing teams is disclosed. Teams may range in size and complexity from a two-person team of roommates to many hundreds in a commercial product development team. Candidates for new or existing teams are identified by matching brainwave response of candidates to the brainwave signature of high-performing, compatible teams. The stimuli of stimulus datasets are rapidly presented to candidates and sensed by any of the five human senses. The signature of a team type is a set of brainwave response characteristics extracted from one or more high-performing, compatible exemplar teams presented with the stimulus dataset and is also distinctly different from other team types or the general population. Closeness of fit between a candidate&#39;s brainwave response and the signature of the exemplar team provides an indication of the likely compatible fit and contribution of a candidate to a high-performing team.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an MMP inhibitor (matrix metalloproteinase inhibitor) inhibiting the decomposition of collagen constituting the periodontal soft tissue and suppressing the breakdown of periodontal tissue, thereby preventing or ameliorating periodontal diseases.  &lt;P&gt;SOLUTION: MMP inhibiting action is developed by including lactoferrin in liposome. The breakdown of a periodontal tissue, especially periodontal soft tissue can be suppressed by orally administering the inclusion product. An oral composition can be prepared by forming the MMP inhibitor in a pharmaceutical form. The use of the inhibitor in the form of a food composition or a medical composition among oral compositions is especially preferable.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
A modified human TNF.alpha. molecule capable of raising neutralizing antibodies towards wild-type human TNF.alpha. following administration of said modified TNF.alpha. molecule to a human host, wherein at least one peptide fragment of the human TNF.alpha. molecule has been substituted by at least one peptide known to contain an immunodominant T cell epitope or a truncated form of said molecule containing an immunodominant epitope and one or both flanking regions of the human TNF.alpha. molecule comprising at least one TNF.alpha. B  cell epitope, wherein the substitution introduces a substantial change in the amino acid sequence of the front .beta.-sheet, in any one of the connecting loops and/or in any one of the B&#39;, I or D strands of the back .beta.-sheet.  The modified human TNF.alpha. molecules or DNA encoding them may be formulated as vaccines against TNF.alpha. optionally with pharmaceutically acceptable adjuvants, for the prevention or treatment of chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases, cancer, disseminated sclerosis, diabetes, psoriasis, osteoporosis or asthma. Human body fluids may be tested for the presence of TNF.alpha. by contact with a composition containing the modified TNF.alpha..
PURPOSE: To provide an adhesive primer capable of preventing the microleakage at the side edge of the cavity surface of the cement and dentin of a restoration part by increasing the adhesion of strength of an adhesive by using the adhesive primer before the application of this adhesive and a pretreating agent capable of enhancing the strength of adhesion by removing a smear layer. CONSTITUTION: This dental adhesive primer contains (A) the compd. of formula I (R&lt;1&gt; , R&lt;2&gt; are lower alkylene), for example, the compd. of formula II, (B) the lower alkyl ester of methacrylic acid having a hydroxyl group in the molecule, for example, 2-hydroxyethyl methacrylate, (C) a polymn. accelerator, for example, methacryloxyethyl-p-(N,N-dimethylamino)benzoic acid (MAEB), camphor quinone and (D) a solvent, more preferably polar solvent and more particularly acetone, ethanol at ratios of A=1 to 10% (wt.), B=10 to 30%, MAEB=0.5 to 10% or camphor quinone 0.1 to 5%. The dentin pretreating agent consists of an alkaline metal salt of the compd. of the formula I, more particularly an aq. 0.2 to 1M soln. of K salt and has pH in a range of 2.4 to 6.0.
A model of a human subject&#39;s head may be generated to assist in a therapeutic and/or diagnostic procedure. A treatment and/or diagnostic system may generate a fitted head model using a predetermined head model and a plurality of points. The plurality of points may include facial feature information and may be determined using a sensor, for example, an IR or optical sensor. One or more anatomical landmarks may be determined and registered in association with the fitted head model using the facial feature information, for example, without the use of additional image information, such as an MRI image. The fitted head model may include visual aids, for example, anatomical landmarks, reference points, marking of the human subject&#39;s MT location, and/or marking of the human subject&#39;s treatment location. The visual aids may assist a technician to perform the therapeutic and/or diagnostic procedure of the human subject.
PROBLEM TO BE SOLVED: To obtain a composition for lips extremely high in luster, excellent in feeling in use such as spreadability and slip and low in smell of a base, by blending specific two oil components known as oil components to produce luster. SOLUTION: This composition for lips is obtained by blending 10-60wt.% of a liquid lanolin with 10-50wt.% of a polyisobutene in &lt;70wt.% of the total of the liquid lanolin and the polyisobutene. The average molecular weight of the polyisobutene is preferably 800-1,200. The liquid lanolin is preferably in &lt;=2,500cps. A hydrogenated liquid lanolin or an adduct of an alkylene oxide to the liquid lanolin may be used as the liquid lanolin. The composition for lips is obtained, for example, in the case of a stick lipstick, by heating and melting the liquid lanolin and the polyisobutene in the amounts, oils and fats and an oily base such as wax, optionally blending the melted substance with a coloring matter, a perfume, a medicine component, etc., until the mixture becomes uniform, packing the mixture into a container and cooling and solidifying.
Systems and methods are provided for evaluating hearing health of a given user. An input audio signal is transformed into the frequency domain and a first and second hearing profile are applied to the input audio sample. The first hearing profile represents a healthy hearing standard and the second hearing profile is the given user&#39;s hearing profile. Using the hearing profiles, first and second perceptually relevant information (PRI) values are generated for the input audio sample. The first and second PRI values are analyzed against each other to generate a PRI index value for the given user, where the PRI index value is a hearing health index value for the given user. The given user&#39;s hearing profile may additionally be applied to differently processed audio samples to evaluate the amount of perceptual rescue offered by various digital signal processing algorithms.
Technologies for attestation techniques, systems, and methods are provided for determining patient movement and conditions. The patient&#39;s movement may be determined by passive indoor positioning technology using channel state information (CSI). Activity data from an activity database may be retrieved from a Wi-Fi access point located in proximity to a monitored space and analyzed to determine an activity trend of a patient in the monitored space. A electronic medical records database may be polled for one or more health events each associated with a set of health parameters. The activity data may be compared to the associated parameter sets of the health events to identify any matches. A notification may be sent to a designated device (e.g., of a caregiver) based on a match between the activity data or trends thereof with the parameter set of a health event,
The present invention relates to a method capable of reducing the fat on the liver with the use of resveratrol in humans with Non-Alcoholic Fatty Liver Disease (NAFLD). Resveratrol has been used in the form of micronized formulation, which has strong antioxidant effects and is circulated at the market as a food supplement. Resveratrol (3, 5, 4&#39; - trihydroxy-trans-stilbene) is a stilbenoid and a phytoalexin produced by several plants. NAFLD is an increasing clinical problem for which effective treatments are required. 
     The study is based on two patient groups. A total of 44 patients (28 men and 16 women) were randomly assigned to groups and were given 50mg resveratrol (n=22) and 200mg (n=22) correspondingly on a daily basis. The patients were followed up for 6 months. Quantity fat measurement, with ultrasound on the liver and kidney, were carried out. There was an initial measurement (time 1) and one after six months (time 2). The study shows the effects of resveratrol on the hepatic enzymes Serum Glutamate Pyruvic Transminase (SGPT) and Gamma- Glutamyl Transpeptidase (g-GT), on the insulin and insulin resistance and on the liver fat. At the end of the study the statistical analysis showed statistical significance reduction on insulin, on the insulin resistance and on the liver fat. These data demonstrate that use of resveratrol improves features of NAFLD, prevents liver damage and that resveratrol can be a new treatment method for NAFLD.
The subject invention concerns materials and methods for treating and/or preventing diseases associated with accumulation of Aβ peptide in neural tissue. The subject invention also concerns materials and methods for treating and/or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and/or treat Alzheimer&#39;s disease and Parkinson&#39;s disease. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant. The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of Aβ peptide in neural tissue, such as Alzheimer&#39;s disease and Parkinson&#39;s disease, using the chemical cotinine.
PROBLEM TO BE SOLVED: To obtain pre-shaving paper powder capable of making excellent sliding of an electric shaver and improving shaving effect. SOLUTION: This pre-shaving paper powder is obtained by peelably attaching spherical powder having 1-50μm radius and 0.92 &lt;= spheroidicity &gt;= 1 on the surface of a substrate is an aerial density of 1-20g/m&lt;2&gt; . Preferably, the substrate has paper-like shape and is formed by using fibers such as Manila hemp or synthetic pulp as a pulp raw material. The spherical powder is formed by a well-known method, using a nylon, etc., having 1-5 Mohs&#39; hardness and coating a mixture of a binder, a dispersant and water on the base plate. When shaving is performed by using an electric shaver, the spherical powder can be applied on the skin of a face and sebum is absorbed in the substrate by coating the powder on the skin of the face. And, use feeling can also be made good without inducing clogging of the electric shaver.
A CELLULAR VIRAL INHIBITOR COMPOSITION          ABSTRACT         A composition for the treatment and prophylaxis of viral infections in mammals is provided.  The composition includes an amount of a contact-blocking viral inhibitor (CVI) in a diluent sufficient to elevate the concentration of the viral inhibitor in a mammal&#39;s tissue above the naturally occurring concentration in that same tissue.  Methods for purifying and concentrating CVI are presented.  The cellular viral inhibitor is characterized by broad antiviral activity, potency, reversible inhibition of viral attachment, cross species activity and molecular size.  Natural levels of CVI range from 6 U/0.1 ml in tears to 400 U/0.1 ml in gastric secretions, with titers between these ranges found in colostrum, milk, plasma, saliva and urine.  Biochemical characterization of the CVI indicates that it resists denaturation by heat, acid and alkali, and it exhibits a molecular size on the order of 2500 daltons.
A diffuser (518) comprises a conduit having a cross-sectional area that increases in a direction fluid flow. In one embodiment, the diffuser is used to reduce the incidence and severity of flow fluctuations that occur in an electrostatic deposition apparatus. In some embodiments, the diffuser includes one or more flow control features. A first flow-control feature comprises one or more appropriately-shaped annular slits (520) through which fluid having a greater momentum than a primary fluid moving through the diffuser is injected into the &#39;boundary layer&#39; near the wall of the diffuser. A second flow control feature comprises one or more annular slits (548) or, alternatively, slots or holes that are disposed at appropriate locations around the circumference of the diffuser through which a portion of fluid flowing in the boundary layer is removed. Boundary-layer flow removal is effected, in one embodiment, by creating a pressure differential across such annular slit or slots. Among other benefits, such flow control features reduce any tendencies for flow separation of the primary fluid in the diffuser.
Microparticles comprising a core, at least one linking carrier on the core, and at least one radioactive therapeutic agent covalently bonded to the linking carrier. The radioactive therapeutic agent may be a radionuclide or a radiopharmaceutical. A method of radiation therapy of a patient by administering to the patient the microparticles. The treatment may be radiation therapy to treat cancer or a tumor. A kit for preparing a microparticle treatment and a method for using the kit to prepare a microparticle treatment dose. The microparticle treatment dose may be made at a location of administration or at a site proximate to the location of administration, such as a local radiopharmacy, laboratory, hospital or physician&#39;s office.
PURPOSE:To obtain the titled powder having the form of short filaments, free from coagulating tendency, and useful as a base of cosmetics, etc., by heating silk yarn etc. with saturated or superheated steam under pressure, releasing the yarn rapidly to a low-pressure atmosphere, and drying and pulverizing the expanded yarn. CONSTITUTION:Silk yarn, etc. (e.g. cocoon, waste cocoon, raw silk, silk fabric, etc.) is, if necessary immersed in hot water, hot water containing soap, sodium carbonate, etc., or warm water containing surface active agent and enzyme to remove the sericin component, and treated with saturated steam under a pressure of preferably 6-13kg/cm&lt;2&gt;G or with superheated steam under a pressure of preferably 5-13kg/cm&lt;2&gt;G at 160-240 deg.C usually for &gt;=10min. The steam-treated silk is released to a low-pressure atmosphere, and the expanded product is dried and made easily pulverizable, and pulverized e.g. with a hammer mill to a fiber length of 30-50mu to obtain the objective powder.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a compound for regulating the activity of an endothelin (ET) peptide, and to provide a formulation for administering the compound to mammals referring to the fact that a vascular endothelium releases various vasoactive materials such as endothelin (ET), etc., which is a vasoconstrictive peptide originating from endothelium.  &lt;P&gt;SOLUTION: Thienyl-, furyl- and pyrrolyl-sulfonamides; pharmaceutically permissible salts of sulfonamides; formulations of the salts and the sulfonamides; and methods for modulating or altering the activity of the peptides of the family of endothelin using the formulations and sulfonamides are provided. In particular, formulations of sodium salts of N-(isooxazolyl)thienylsulfonamides, N-(isooxazolyl)furylsulfonamides and N-(isooxazolyl)pyrrolylsulfonamides are provided. A method for preparing an alkali metal salt of hydrophobic sulfonamides is provided. The method includes a step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and a step of recovering the formed sulfonamide salt from the organic solvent.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT